Table 2.
Summary of main studies reporting CCP usage in oncohematological patients
| Type of tumor | n | CCP regimen | Outcome | Notes | Ref |
| NHL MM ALL HL MF CLL |
5 4 2 1 1 1 |
High-titer (≥1:320) CCP | - Overall mortality rate 41.2% (10/24) - Overall mortality rate in hematological cancers: 35.7% (5/14) - Mortality in non-intubated patients: 6/21 (28.5%) |
Clinical benefit of CP when administered in less advanced COVID-19 |
[54] |
| NHL CLL WM |
11 3 1 |
4 CCP units (titer ≥ 1:40) |
- Rapid viral clearance following CCP - Overall mortality rate 6.7% (1/15) |
CCP is a promising therapy for COVID-19 B-cell depleted patients | [37] |
| NHL | 5 | 2 high-titer (≥1:160) CCP units | - Increase in neutralizing antibody titer following CCP - Overall mortality rate 20.0% (1/5) |
Patients with B-cell-depleted lymphomas are ideal candidate for CCP | [48] |
| NHL AL MM CML MDS |
18 4 7 2 2 |
1–2 CCP (>1:640)1 |
- Overall mortality rate 45.5% (15/33) - No mortality difference between early (< 7 days) versus late CCP transfusion |
Study with limitations (retrospective case series) | [53] |
| Lymphoid neoplasms Myeloid neoplasms |
12,321 | NA | - Adjusted 30-day mortality: HR 0.60; 95% CI 0.37–0.97 | CP is associated with improved survival in patients with hematologic malignancies | [52] |
| NHL CLL MF AML |
4 1 1 1 |
3 CCP units | - No deaths recorded - Viral clearance in 5/7 (71.4%) - No adverse effects |
CP is associated with clinical and radiological improvement in oncohematological patients | [50] |
Legend: CCP, COVID-19 convalescent plasma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; ALL, acute lymphoblastic leukemia; MF, myelofibrosis; CLL, chronic lymphocytic leukemia; WM, Waldenstrom macroglobulinemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NA, not available; HR, hazard ratio; AL, acute leukemia; AML, acute myeloid leukemia;
1Serologic assay.